Seven-Year Follow-Up Results Can Help HER2+ Breast Cancer Patients Avoid Overtreatment

Leggi l'articolo originale


The combination of trastuzumab and paclitaxel ‘represents an important step forward in de-escalating therapy’ for HER2+ breast cancer.

Lascia un commento